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Major basic protein (MBP) released from activated eosinophils may inﬂuence airway hyperresponsiveness (AHR) by either direct
eﬀects on airway myocytes or by an indirect eﬀect. In this study, human bronchi, freshly isolated human eosinophils, or MBP
puriﬁed from human eosinophil granules were incubated for studying eosinophil inﬁltration and MBP localization. Eosinophils
immediately adhered to intact human airway as well as to cultured human airway myocytes and epithelium. Following incubation
18–24 h, eosinophils migrated into the airway media, including the smooth muscle layer, but had no speciﬁc recruitment to airway
neurons.EosinophilsreleasedsigniﬁcantamountsofMBPwithintheairwaymedia,includingareascomprisingthesmoothmuscle
layer. Most deposits of MBP were focally discrete and restricted by immunologic detection to a maximum volume of ∼300μm3
about the eosinophil. Native MBP applied exogenously was immediately deposited on the surface of the airway, but required at
least 1h to become detected within the media of the airway wall. Tissue MBP inﬁltration and deposition increased in a time-
and concentration-dependent manner. Taken together, these ﬁndings suggest that eosinophil-derived cationic proteins may alter
airway hyperresponsiveness (AHR) in vivo by an eﬀect that is not limited to the bronchial epithelium.
1.Introduction
Asthma is a chronic inﬂammatory disease of the airways,
which reduces airway luminal diameter by several mech-
anisms, including increased airway mucus, airway edema,
and airway smooth muscle activation. A histologic hallmark
of clinical and experimental asthma is the prevalence of
eosinophils within, and inﬁltrating, the airway wall [1, 2].
In asthma deaths, the eosinophilic inﬂammation is more
intense than in mild-to-moderate asthma [3]. However, in
peripheral airways the eosinophilic inﬁltration is signiﬁcant
even during atopic asthma in remission [4, 5]. The presence
of airway eosinophils in asthma is in stark contrast to their
near total absence in healthy persons. Eosinophil granules
contain proteins, including major basic protein (MBP),
which are highly basic and cationically charged and may
inﬂuence airway cell function and cause AHR [6]. Recently,
the role of the eosinophil in asthma has been questioned
as anti-IL-5, which eﬀectively depleted eosinophils from the
blood and induced sputum in mild atopic subjects with
asthma, but had no eﬀect on AHR [7]. However, in similar
studies, anti-IL-5 also had no eﬀect on bronchial mucosal
staining of intracellular and extracellular MBP [8]. In these
studies the MBP deposition was only evaluated at the level
of the airway mucosa. Thus, the lack of eﬃcacy of anti-IL-
5 on AHR via granule protein inhibition was incompletely
understood.
Prior investigations, both in vivo [9, 10] and in vitro
[11–14], using direct, but brief, applications of puriﬁed MBP
have suggested that the eﬀect of MBP on smooth muscle
cell contraction is indirect and likely mediated via barrier
interruptionoftheairwayepitheliumorbyalteringepithelial
mediator release [15]. However, these prior investigations
rest on the hypothesis that cationic peptides delivered to
the airway luminal surface mimic in vivo eosinophil granule
protein release and that granule protein release never occurs
within the airway wall. An analysis of the extracellular
deposition of granule proteins within the airway wall has2 Mediators of Inﬂammation
(a) (b)
Figure 1: (a) Example of intense inﬂammatory inﬁltration of eosinophils into the lamina propria in airway of asthmatic patient (H&E stain;
600x). Note discrete localization of eosinophils within the ASM layer. (b) Example of immunoﬂuorescence staining of MBP in the ASM layer
of an asthmatic patient (anti-MBP; 600x). In addition to the lamina propria, MBP was clearly localized in the smooth muscle layer.
been conducted in guinea pig models of asthma. In those
studies, “M2 receptor dysfunction” is “restored” by an
antibody to MBP [16], or by the MBP antagonist heparin
sulfate [17]. These results suggest that extracellular MBP
deposition does occur within the airway wall. However, these
studies leave open the possibility of a direct eﬀect of MBP
on airway myocytes. In an index case of a patient who died
of status asthmaticus, we identiﬁed eosinophils, as well as
extracellular MBP within the smooth muscle layer (Figures
1(a) and 1(b)). Moreover, we have previously demonstrated
in cultured airway myocyte preparations that MBP directly
alters cellular calcium homeostasis, suggesting the possibility
that MBP may directly augment smooth muscle contraction
[18]. It is possible that airway preparations are relatively
impermanent to the direct application of MBP. Several
investigators have qualitatively noted MBP within the airway
wall of patients with asthma [4, 5, 19, 20]. But, in none of
these studies was an analysis of the MBP performed such
that the granule protein localization could be diﬀerentiated
between intracellular and extracellular deposition, nor was
a precise localization of the eosinophils in relative distance
anddistributiontomyocytesandairwayneuronsestablished.
Thus, the physiologic eﬀects of MBP on human airway
smooth muscle remain uncertain.
As MBP is transported directly to individual airway cells
following eosinophil migration, activation, and degranula-
tion, we sought to understand the potential role of MBP on
airway cells by determining the spatial localization of both
MBP and eosinophils following direct application of either
puriﬁed MBP as well as following its in vitro release from
human eosinophils.
2. Methods
2.1. Human Bronchi Isolation. Human bronchi were
obtained from surgical specimens in accordance with
procedures approved by the Mayo Clinic Foundation
Institutional Review Board. Tissues obtained were incidental
to the patient’s surgery and were discarded by the surgical
pathologist. The total subjects were 22, airways from 15
subjects were incubated with eosinophils, and airways
from 9 subjects were incubated with MBP. All tissues
were immersed in ice-cold HBSS (Hanks balanced salt
solution with 2.25mM CaCl2,0 . 8m MM g S O 4 and 12,mM
glucose; pH 7.4). 3rd to 6th generation bronchi were
freed from adherent tissue using a dissecting microscope.
Bronchial segments (4-5mm length, 1-2mm diameter)
w e r ep r e p a r e da n dk e p ti ni c e - c o l do x y g e n a t e dH B S S
until use in experimental protocols. For incubation
studies bronchial segments were washed thoroughly and
transferred to eight-well Lab-Tek glass cover slides (Nunc,
Naperville, IL) in DMEM supplemented with 10% FBS
and antibiotics/antimycotic (penicillin, streptomycin, and
amphotericin B) and maintained in a 5% CO2 humidiﬁed
incubator at 37◦C.
2.2. Human Bronchial Smooth Muscle and Epithelial Cell
Isolation and Culture. Human bronchi were obtained and
epitheliumwasremovedasdescribedaboveforuseinhuman
bronchi isolation. Primary smooth muscle cultures were
prepared as previously reported [21]. Brieﬂy, third- to sixth-
generation bronchi were immersed in icecold HBSS aerated
with 100% O2. Under a dissecting microscope, epithelium
was removed, and the remaining tissue was ﬁnely minced
in icecold Ca2+-free HBSS. The HBSS was removed, and the
tissue was incubated for 1h at 37◦C in Earl’s balanced salt
solution(EBSS)containing30mg/mLBSA,20U/mLpapain,
and 0.005% DNase (Worthington Biochemical, Lakewood,
NJ). After 1h, 1mg/mL of type IV collagenase and 0.4U/mL
elastase were added for an additional 45min at 37◦C. The
tissue was gently triturated, centrifuged, and redispersed
several times in EBSS with ﬁnal resuspension in DMEM/F-
12mediumcontainingantibiotics/antimycotic and10% fetal
bovineserum.Theﬁnalresuspensionwasseededintoculture
ﬂasks.
All cultures were maintained in a humidiﬁed atmosphere
of 5% CO2 and 95% air at 37◦C. Upon reaching 70%–
90% conﬂuence, cells were passaged and plated for use
in experiments. Cells were used between passage 1 and
2 for all experiments. Presence of smooth muscle cellsMediators of Inﬂammation 3
was conﬁrmed by immunohistochemistry. For epithelial
cell isolation, bronchial segments were dissected clean of
adherent connective tissue and placed (with both ends
ligated) into sterile HBSS. The lumen was ﬁlled with 0.1%
Protease (Sigma) for 1 to 2 hr at 37◦C. Subsequently, cells
were mechanically loosened from the airway lumen with a
rounded spatula suspended in HBSS for centrifugation at
600rpm. The resulting cell pellet was then washed (twice)
and resuspended in HBSS with 10% FCS. Cells were seeded
on to Type IV collagen coated glass cover slides in F12
with epithelial growth factor, Triiodothyroxine, penicillin
and 10% FCS and grown to conﬂuence in 2–4 days.
2.3. Isolation of Human Eosinophils. Human eosinophils
were isolated as previously described [22]. Brieﬂy, hep-
arinized blood was collected from atopic and nonatopic
volunteers,andequalvolumeof1×PIPESwasadded,andthe
diluted blood was layered onto Percoll (density 1.085g/mL).
After centrifugation at 1000g for 30 minutes at 4◦C, the
plasma and Percoll layers were removed by aspiration. Tubes
were wiped to remove contaminating leukocytes, and red
cells were lysed by osmotic shock. The remaining pellet,
containing neutrophils and eosinophils, was incubated with
an equal volume of anti-CD16 magnetic beads (Miltenyi
Biotec, Auburn, CA) on ice for 30 minutes. After incubation
the cell mixture was diluted with 1 × PIPES + 1% calf serum
(HyClone Laboratories, Logan, UT) and eluted through a
steel wool column suspended in a strong magnet. Column
eluate (14mL) was collected and the number of eosinophils
was determined by staining with Randolph’s stain.
2.4. Isolation Human MBP. Eosinophils as isolated above
were lysed with sucrose and heparin, and the granules were
collected by centrifugation. Granules were lysed by exposure
to 0.01M HCL, pH 2, and by sonication. Insoluble materials
were removed by centrifugation and the lysate was applied to
a Sephadex G-50 column, equilibrated with 0.025M sodium
acetate buﬀer, with 0.15M NaCl, pH 4.2. The third peak
f r a c t i o n sw e r ep o o l e da sM B P[ 23].
2.5. Incubation of Bronchial Segments or Airway Cells with
Eosinophils or MBP. Freshly isolated eosinophils were added
towells(ﬁnalvolumeofmedia =400μLperw ell)whic hc on-
tained bronchial segments or cultured airway myocytes and
epithelium. The ﬁnal concentration of isolated eosinophils
i na l lg r o u p sw a s2 . 5× 106 cells/mL. After 10min and
during direct video microscopy nonadherent eosinophils
were removed by washing 3 times with fresh media. Using
a calibrated optical grid, the number of adherent cells
remainingwascountedandrecorded.Airwaysmoothmuscle
cultures were ﬁxed in 10% formalin for 2min at room
temperature and eosinophils were identiﬁed using Wright’s
stain.
For prolonged incubation, to determine the localiza-
tion of eosinophils and/or immunoreactive MBP, bronchial
segments were exposed to either eosinophils or MBP, and
incubated for 24h in medium (400μL) ± eosinophils (2.5 ×
106 cells/mL) + IL-5 (100pg/mL) for 18h. IL-5 was added to
the medium as it has previously been determined necessary
to prevent eosinophil apoptosis in vitro [24]. In bronchi
incubated with eosinophils 4h prior to ﬁxation, 25ng/mL
of IL-5 was added for additional 4h to promote eosinophil
degranulation [25]. In bronchial segments incubated with
puriﬁed MBP (10−9–10−5 M) the incubation time varied
between 1min, 1h, or 24h. Following incubation tissues
were ﬁxed and immunostained as described below.
2.6. Histology and Fluorescent Immunohistochemistry for
Analysis of Eosinophils Location and Immunoreactive MBP.
First to identify and quantify the possibility of migration
of eosinophils into bronchial segments in vitro, histologic
stains were used. Speciﬁcally, to identify eosinophils fol-
lowing overnight incubation of bronchial segments with
eosinophils, segments were imbedded in Tissue-Freezing
Medium (Triangle Biomedical Sciences, Durham, NC) and
snapfrozeninisopentaneprecooledinliquidnitrogen.10μm
serial sections were then cut and stained with hematoxylin
and eosin (H&E) for conventional histologic examination;
additional sequential sections were stained for eosinophils
with Wright’s stain. Only “unambiguous” cells with eosin
containing granules were identiﬁed as eosinophils and quan-
tiﬁed per cross-sectional area. Eosinophils were identiﬁed as
within the smooth muscle layer if all, or part of the cell,
contacted an unambiguous smooth muscle cell. We then
quantiﬁed the number of eosinophils within the smooth
muscle layer. As histologic stains are less sensitive than
immunostaining for eosinophils, we likely undercounted the
total number of eosinophils which migrated into tissues
compared to control tissues.
Other bronchial sections were immunostained for MBP
and smooth muscle actin. Filley et al. have shown that
the antibody is speciﬁc for MBP because it stained only
eosinophils in the peripheral blood and because its activity
is removed by absorption with MBP [26]. Brieﬂy, sections
wereﬁxed in ice-coldacetone:methanol (60 : 40) for10min,
washed with 0.3% triton x –100 in tris buﬀered saline (TBS)
with tween 20 (TBST; pH 7.6), and air dried. Sections
were blocked in 10% donkey serum in TBST for 1h, 1%
chromotrope 2R to block nonspeciﬁc binding of ﬂuorescein
dye to the eosinophils [27]. Sections were then incubated
with the primary antibodies (MBP 1 : 60, actin 1 : 500,
protein gene product (PGP) 1 : 200 alone, or in combi-
nations) diluted in 1% donkey serum in TBST for 2h at
room temperature. Control sections were treated identically
in the absence of primary antibodies. After incubation with
the primary antibodies, the sections were rinsed with TBST
and treated with Cy3 (1 : 200) and Cy5 (1 : 500) conjugated
species,speciﬁcsecondary antibodies for45 minutes atroom
temperature. MBP and actin immunoreactivity were imaged
with an Olympus FluoView confocal microscope mounted
on a BX50WI microscope (Olympus America, Melville, NY).
An Olympus Dapo × 40/1.3 NA oil-immersion objective
was used for imaging. Serial confocal optical sections were
obtained by moving the stage in only one direct. Each optical
section was digitized and stored in arrays of 800×600 pixels.
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and were found to be 0.5 × 0.5μm for the xy-plane. The
calculated thickness of optical sections was matched to this
dimension such that each voxel was 0.25μm3. These values
wereusedtocalculatethevolumeofMBP,whichsurrounded
degranulated eosinophil “ghosts.”
Onsomeimagescomputeranalysisofsectionsstainedfor
MBP by immunoﬂuorescence was performed to objectively
evaluate the overall areas covered by MBP and smooth
muscle. Digital images obtained above were selected for
maximal ﬂuorescence staining of either MBP or actin. Imag-
ing and acquisition parameters were initially determined to
verifylackofphotobleachingorvisiblephotodamage.Digital
images of the next section in a series which were stained
with normal rabbit IgG served as a negative control and
were recorded. A threshold setting was acquired for each
negative control image so that pixel values were near zero
and images and subsequently positively stained images were
acquired at these settings. Both camera background (dark
current) and image background (taken from ﬂuorescent
image signal collected from random 10–12 ROIs of the
negative control specimens) were determined daily and
subtracted from the collected quantiﬁed image ﬂuorescence.
In addition, xenon lamp intensity, image acquisition time,
and image pixel binning were ﬁxed and controlled such
that all image signals remained within the 12bit dynamic
intensity range of our digital camera, and thus could be
reliably compared across experiments. We identiﬁed MBP as
beingpresentatatissuesite(voxel)iftheﬂorescentsignalwas
>5% above background in our 4095 dynamic range 12bit
imaging system. This value was chosen because maximal
ﬂorescent intensity in tissues treated with exogenous MBP
(10
−5 M) typically gave intensity values of ∼2500 following
image correction. Given these constraints, we could only
underestimate, but never overestimate, the presence of MBP.
Later images were deconstructed into an image speciﬁc for
smooth muscle actin and one speciﬁc for immunoreactive
MBP using Metamorph (Molecular Devices, Sunnyvale, CA,
94089). Subsequently these two images were masked and
binarized so that the percentage of actin speciﬁc smooth
muscle and MBP could be determined as well as the relative
area that was colabeled.
2.7. Quantiﬁcation of Eosinophils and Extracellular MBP in
the Vicinity of PGP 9.5 Positive Airway Neurons. Follow-
ing overnight incubation of 2mm human bronchi with
eosinophils, histological sections were prepared and dou-
ble immunostained with nonspeciﬁc neuronal cell marker
anti-PGP 9.5 and anti-MBP. A 10μmg r i dw a so v e r l a i d
onto images collected with 400X magniﬁcation. All squares
within sections of each airway were counted as containing
intact eosinophils, extracellular MBP, PGP 9.5 neurons,
or combinations, or none of above. Percentage of squares
containing PGP 9.5 and eosinophils or extracellular MBP
were determined and compared to the percentage of squares
not containing PGP 9.5 neurons.
2.8. Determination of Eotaxin Presence in Unstimulated
Human Airway by Fluorescent Immunohistochemistry.
Because we found exogenously added donor eosinophils
migrating within unstimulated human airway following
incubation, we determined whether expression of EOTAXIN
was present by immunostaining as above. Serial sections
were immunostained for MBP and Eotaxin, as above (MBP
1:60, Eotaxin 1:50), and diluted in 1% donkey serum in
TBST for 2h at room temperature. Control sections were
treatedidenticallyintheabsenceofprimaryantibodies.After
incubation with the primary antibodies, the sections were
rinsed with TBST and treated with Cy3 (1:200) and Cy5
(1:200) conjugated species, speciﬁc secondary antibodies
for 45 minutes at room temperature. MBP and Eotaxin
immunoreactivity were imaged with an Olympus FluoView
confocal microscope mounted on a BX50WI microscope
(Olympus America, Melville, NY).
3.Materials
Human eosinophil-derived MBP in Na acetate buﬀer (pH
4.0, ∼1–3mg/mL) and human eosinophils were obtained
from the laboratory of Dr. Hirohito Kita (Mayo Clinic,
Rochester, MN). DMEM and antibiotic/antimycotic mix-
tures were obtained from Gibco-Invitrogen, Carlsbad, CA.
Interleukin-5 was a gift from Schering-Plough, Kenilworth,
NJ. Mouse monoclonal antibody for MBP, and goat poly-
clonal antibody for actin, goat polyclonal antibody for
Eotaxin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Rabbit polyclonal antibody for PGP 9.5
was purchased from Biogenesis. Cy3-conjugated aﬃnity-
puriﬁeddonkeyanti-mouseIgGandcy5-conjugatedaﬃnity-
puriﬁed donkey anti-goat and anti-rabbit IgG were pur-
chased from Jackson ImmunoResearch Laboratories, Inc.
(West Grove, PA). Human plasma ﬁbronectin was purchased
from Gibco-Invitrogen Corporation, Carlsbad, CA. Collagen
was purchased from Vitrogen 100, Cohesion, Palo Alto, CA.
Bovine serum albumin was purchased from Sigma-Aldrich,
St. Louis, MO.
4.DataAnalysis
In all experiments, diﬀerences between two groups were
analyzed for statistical signiﬁcance using either a one-way
analysis of variance (ANOVA) or a Student’s t-test (two-
tailed) for unpaired sample. In the case of ANOVA, a
multiple-comparison test was used to compare all groups. A
value of P ≤ .05 was accepted as signiﬁcant. All results are
expressed as mean ± S.E.
5. Results
5.1. Patient Characteristics. Using established guidelines
[28], subjects were classiﬁed into normal lung function, or
mild, moderate, and severe COPD. Speciﬁc characteristics of
each group including smoking history are listed in Table 1.
Among the 22 subjects, 17 had bronchogenic carcinoma; the
other 5 had bronchoalveolar carcinoma (1), carcinoid (1),
metastatic sarcoma (1), mycetoma (1), and bronchopleural
ﬁstula (1).Mediators of Inﬂammation 5
(a) (b)
Figure 2: (a) Human eosinophils immediately (<10min) adhere to freshly isolated human airway in vitro. Human eosinophils adhere to
adventitial surface of human airway and epithelial surface (not seen) (bronchial diameter = 1.5mm, phase contrast 100x). (b) Eosinophils
immediately (<10min) adhere to cultured human airway myocytes. Wright’s stain of eosinophils adhering to passage 1 serum-deprived
elongated airway myocytes (phase contrast 600x).
(a) (b)
Figure 3: Following overnight incubation adherent eosinophils migrated within the airway wall, including the smooth muscle layer.
Eosinophils were found within the epithelium, subepithelium, smooth muscle layer, and loose connective tissue. These panels represent
examples of eosinophils identiﬁed by Wright’s staining (a) and H&E staining (b) within the airway wall; arrows denote eosinophils (600x).
5.2. Identiﬁcation by Immunoﬂuorescence of MBP in Smooth
Muscle Layer of a Patient with Asthma. In formalin-ﬁxed,
paraﬃn-embedded lung tissue obtained post mortem from
a patient who died due to asthma (Figure 1(a)), indirect
immunoﬂuorescence (Figure 1(b)) showed areas of extracel-
lular MBP immunoﬂuorescence within the smooth muscle
layer. These areas showed few intact eosinophils in a sea of
eosinophilic granular debris, which stained intensely with
anti-MBP. These results strongly suggest that in addition to
necrotic areas in the lamina propria and damaged epithelial
surfaces, in this one patient with asthma, MBP was released
within the smooth muscle layer of the airway.
5.3. Eosinophils Immediately Adhere to Human Airway In
Vitro and Cultured Human Airway Myocytes and Epithelium.
Repeated observations by phase contrast microscopy (n =
3 bronchial segments from 5 distinct patients) revealed
that exogenously applied unstimulated eosinophils adhered
immediately (<10min) to the adventitial and epithelial
surface of 2mm human airways (Figure 2(a))a sw e l la s
to the surface of the glass chamber. Within 10 minutes
the attachment appeared durable, as direct rinsing of the
tissue with fresh media elicited no discernible detachment
of eosinophils. Similarly, exogenously applied unstimulated
eosinophils adhered immediately (<10min) to surfaces of6 Mediators of Inﬂammation
Figure 4:Representativeimageshowingdistributionofimmunore-
active MBP and smooth muscle actin within 2mm human
airway following overnight incubation with human eosinophils.
Immunoreactive actin (green) and MBP (red) are shown. Two
patterns of extracellular MBP deposition are noted broad linear
deposition along luminal and abluminal surfaces, and (arrows)
discrete focal deposition within the airway media, especially in the
vicinity of airway myocytes (confocal microscopy 400x).
10μm
Figure 5: Distribution of immunoreactive MBP domain within
human airway following overnight incubation with human
eosinophils. MBP (green) is shown as focal deposits. Arrows
indicate eosinophil “ghosts” (confocal microscopy 600x).
cultured (passage 1-2) human airway myocytes (Figure 2(b))
and primary human airway epithelium (not shown). Similar
to fresh tissue, the attachment was durable, as direct rinsing
ofthe tissue withmedia during observed microscopy showed
no discernible detachment of eosinophils from the cells.
Immediate eosinophil adherence to cultured ASM and
epithelium was 10 ± 3, 20 ± 5%, respectively, n = 3
determinations from Wright’s stained cover slides of ASM
cells from 5 distinct patients of the eosinophils added to
the culture system. The attachment was Ca2+ dependent
as media with 0.0mM Ca2+ and 0.3% EDTA completely
prevented eosinophil attachment.
5.4. Eosinophils Migrate within the Airway Wall, Including
the smooth Muscle Layer. Following eosinophil incubation
of small human airways for 18–24h, eosinophils, identiﬁed
Table 1: Patient characteristics and pulmonary function tests.
Patient characteristics Number
Age (yr)∗ 63.8 ± 9.0
Sex (Male/Female) 10/12
Smoking pack years∗ 33.4 ± 13.6
Current = 6
Smoking history Past = 12
Never = 4
Current corticosteroid use 2
Pulmonary function
Classiﬁcation of COPD
Normal 1
Mild COPD 5
Moderate COPD 8
Severe COPD 8
Positive bronchodilator
Response 3/17
∗Values are means ± SD.
by Wright’s or H&E stain, migrated within the airway wall,
including into the smooth muscle layer (Figures 3(a) and
3(b)). The total numbers of eosinophils found within the
airway were 557 ± 68 per cross-section of ∼2mmairways
(n = 3 airway sections from 11 distinct patients). The total
numbers of eosinophils found within or adjacent to the
airway smooth muscle layer were 124.9 ± 18.1 per cross-
section of ∼2mm airway (n = 5a i r w a ys e c t i o n sf r o m5
distinct patients). In tissues incubated without eosinophils
(control tissues), total eosinophils within the entire airway
were 3 ± 1 and eosinophils within or adjacent to the airway
smooth muscle layer were 0 ± 0 per cross-section of ∼2mm
airway (n = 3 airway sections from 11 distinct patients in
both groups).
5.5. Distribution of Immunoreactive MBP and Smooth Mus-
cle Actin in Human Airway Bronchus following Overnight
Incubation with Human Eosinophils. Following overnight
incubation with eosinophils, immunoreactive MBP was
demonstrated over 16.8 ± 3.2% (n = 5a i r w a ys e c t i o n s
from 15 distinct patients) of the airway volume (Figure 4).
Using immunoreactive smooth muscle actin to determine
the location of airway myocytes, binarized colabeled images
demonstrated that 23.8 ± 4.9% (n = 5a i r w a ys e c t i o n sf r o m
15 distinct patients) of the total MBP content was resident
in a smooth muscle speciﬁc locus. Eosinophil degranulation
was evident by two patterns of extracellular MBP deposition.
A broad linear deposition occurred along both the adven-
titial and epithelial surface. In addition confocal scanning
microscopy determined that the MBP deposition within the
media occurred as discrete focal deposition occurring within
the airway media, including the airway myocyte. These focal
deposits of MBP were demonstrated as both intracellular
M B Pa sw e l la se x t r a c e l l u l a r l yr e l e a s e dM B P( v i d ei n f r a ) .I n
all control tissues no MBP content was observed.Mediators of Inﬂammation 7
Media 1min
(a)
Media 1h
(b)
MBP 10−9 m1m i n
(c)
MBP 10−9 m1h
(d)
MBP 10−7 m1m i n
(e)
MBP 10−7 m1h
(f)
MBP 10−5 m1m i n
(g)
MBP 10−5 m1h
(h)
Figure 6: Immunolocalization of exogenously applied MBP in human airway. Results show representative images analyzing the ﬂuorescence
of immunolabeled MBP in human airway following incubation with MBP for 1min and 1h. Immunoreactive actin (green) and MBP
(red) are shown. Brief Exposure. 1min elicited limited MBP deposition to the epithelial and outer surfaces of the airway. However,
longer 1h exposure allowed some MBP to access cells within the media of the airway wall. The longer 1h exposure was necessary for
immunolocalization to be detected within the smooth muscle layer. This time-dependent eﬀect was increased by greater concentrations of
MBP (10−5 M) compared to lesser concentrations of MBP (10−7 M). In all control tissue no MBP content was detected (confocal microscopy
400x).
5.6.MicrodomainofMBPReleasefromIndividualEosinophils.
Confocal laser scanning of areas of MBP staining within
the airway media demonstrated both intracellular MBP as
well as restricted extracellular microdomains of MBP with
“ghosts” representing degranulated eosinophils (Figure 5).
The immune detected microdomain of MBP released
from individual eosinophils within the human airway was
observed to be restricted to an average of 317.5 ± 43.5μm3
from the center of a ghost eosinophil within the airway
(n = 5 determinations each per 10 patients). Similarly the
microdomain of MBP released from individual eosinophils
at sites along the perimeter of the airway (either luminally,
or abluminally) was restricted to an average of 628.5 ±
213.9μm3(n = 5 determinations each per 10 patients).
5.7. Distribution of Immunoreactive MBP and Smooth Muscle
Actin in Human Airway Bronchus following Exogenously
Applied MBP in Human Airway. Figure 6 shows representa-
tive images from identical experiments performed in airways
from 9 distinct patients of immunolabeled MBP in human
airway following incubation with MBP for 1min and 1h.
Brief exposure, 1min (Figure 6), resulted in limited MBP
deposition to the epithelial and outer surface of the airway.8 Mediators of Inﬂammation
Figure 7: Overnight incubation of human airway with exogenously
applied MBP. This representative image shows ﬂuorescence of
immunolabeled MBP (red) in human airway following incubation
with MBP 10−5 M overnight. Compared to lesser duration of
exposure (Figure 6), longer exposure, overnight, allowed MBP
greater access to cells within the media of the airway wall. Notably
this longer exposure allowed for signiﬁcant immunolocalization
to be detected within the smooth muscle layer (green) (confocal
microscopy 400x).
However, longer exposure, 1h, allowed some MBP to access
cells within the media of the airway wall. More impor-
tantly, longer exposures allowed for immunolocalization to
be detected within the smooth muscle layer. This eﬀect
was increased by greater concentrations of MBP (10−5 M)
compared to lower concentrations of MBP (10−7 M). In all
control tissue, smooth muscle actin was detected but no
MBP content was detected (Figure 6, top panels). Compared
to 1min and 1h duration of exposure (Figure 6), longer
overnight exposure (Figure 7) allowed MBP greater access to
cells within the media of the airway wall, especially within
the smooth muscle layer. A summary of the time- and
concentration-dependent eﬀects of the access of MBP to the
smooth muscle layer is shown in Figure 8.
5.8. Distribution of Immunoreactive MBP and Neuron-Speciﬁc
PGP 9.5 in Human Airway Bronchus following Overnight
Incubation with Human Eosinophils. In sections of human
bronchi, eosinophils and extracellular MBP were found
within airways following 18–24h incubation with human
eosinophils. Airway neurons were identiﬁed immunohisto-
chemically by an antibody against PGP 9.5, a nonspeciﬁc
neural marker for ubiquitin C-terminal hydrolase found in
neuroendocrine bodies and nerves [29]. Eosinophils and
extracellularMBPwereidentiﬁedusinganantibodyforMBP
(data not shown). The relative area staining for PGP 9.5
with MBP was not signiﬁcantly diﬀerent from the relative
area staining positive for MBP not containing PGP 9.5.
Speciﬁcally, the relative area of PGP 9.5 positive and MBP
positive was 7.0 ± 3.0 percent compared to PGP 9.5 negative
and MBP positive 5.9 ± 1.3 percent, (P>. 7, n = 3
determinations from 10 distinct patients). However the
relative area containing eosinophils and PGP 9.5 positive
neurons was signiﬁcantly less than the relative non-PGP 9.5
area containing eosinophils. Speciﬁcally, the relative non-
PGP 9.5 area also containing eosinophils was 2.8 ± 0.65
percent compared to only 0.70 ± 0.60 percent of the relative
PGP 9.5 positive area, (P<. 03 n = 3 determinations from
10 distinct patients). Thus, there was no evidence of speciﬁc
recruitment of eosinophils, nor eosinophil degranulation in
the area of PGP 9.5 neuronal tissue compared to the rest of
the airway wall (Figure 9).
5.9. Eosinophils Location and Immunoreactive MBP and
Eotaxin. To determine the expression of the chemokine
Eotaxin in our cultures, we determined by qualitative
immunoﬂuorescent microscopy the localization of Eotaxin
as well as MBP in human airways incubated 18h with and
without eosinophils. There were no apparent diﬀerences
(n = 3 determinations from 5 distinct patients) in Eotaxin
expression (Figure 10) which occurred constitutively within
thebronchialepitheliumandairwaywallintissuesincubated
both with and without eosinophils.
6. Discussion
Eosinophilic airway inﬂammation is a dominant ﬁnding
in human asthma, as well as in some patients with
smoking-related COPD [30]. The present study indicates
that eosinophils can attach and migrate into the media of
unsensitized small human airways in vitro and many of
these eosinophils colocalize to airway smooth muscle cells.
Furthermore, these eosinophils may degranulate in vitro
allowing for analysis of MBP localization along the surfaces
and within the media of the airway. Moreover, incubation of
small human airways with isolated MBP reveals a distribu-
tionkineticwhichisbothtimeandconcentrationdependent.
In addition we determined that MBP’s diﬀusion is restricted
to the airway surface during brief and low concentration
incubation, but may penetrate the airway media and eﬀect
medial layer cell function, during either prolonged high-
concentration incubation or during incubation with the
“MBP carrier cell”, the eosinophil. This restricted diﬀusion
distribution is likely due to MBP’s large cationic charge [31].
Our ﬁndings explain the conﬂicting results that prior
studies have produced following the application of MBP to
intact airway or cultured airway cells. These prior studies
have diﬀered in that MBP’s eﬀects on airway smooth muscle
may be direct [18] or indirect [10]. We [18] have previously
shown that MBP directly elicits airway myocyte calcium
mobilization. Others have shown that an indirect eﬀect
of MBP may be through an eﬀect on epithelial-derived
mediator release [32–34], increased epithelial permeability
[35], cytotoxicity [36], or by inhibiting muscarinic M2
receptors [16]. These conﬂicting results may be due to the
manner in which puriﬁed MBP is applied to tissues and
cells in culture. Though the eosinophil transports MBP in
a solubilized form within specialized acidiﬁed granules to
prevent its precipitation and premature binding to cells
[37], the application of puriﬁed MBP directly to tissues
and cells is problematic. For example, experimental [10]
application of high concentrations (1mg/mL, 71μM) forMediators of Inﬂammation 9
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Figure 8: Immunolocalization of MBP in human airway following exogenous application of MBP or following incubation with eosinophils.
Separate images showing smooth actin and MBP were examined. (a) shows MBP distribution (red), (b) image shows smooth muscle actin
(green), and (c) image shows putting the two images together in binarized colabed images. Using the Metamorph system, the two pictures
were analyzed to ﬁnd areas measured in pixels. Exposure of 1min (solid) or 1h (light gray) as to higher concentrations of MBP allowed
more MBP to access smooth muscle area compared to lower concentrations no signiﬁcance was found by percentage smooth muscle with
MBP in smooth muscle area. For same concentrations, longer exposure, 1h compared to shorter exposure, 1min, increased the percentage
of smooth muscle colocalized with MBP. Additionally, substantial MBP (23.8%± 4.9) was found in the ASM layer following overnight
incubation (black) with human eosinophils (n = 3 determinations from 9 patients for each concentration and time).
(a) (b)
Figure 9: Distribution of immunoreactive MBP and nerve PGP 9.5 in human airway following overnight incubation with human
eosinophils. Representative images of 2mm human airway incubated overnight with eosinophils. Immunoreactive PGP 9.5 (green) and
MBP (red) are shown. Though some eosinophils appeared near nerves (small arrows) in the human airway (a), many eosinophils, as
well as extracellular MBP deposition, occurred within the airway wall not associated with airway nerves (b) (thick arrows) under higher
magniﬁcation (confocal microscopy 400x).10 Mediators of Inﬂammation
Eotaxin −
(a)
Eotaxin +,
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(c)
Figure 10: Eosinophils location and immunoreactive MBP and Eotaxin in human airway following overnight incubation with and without
human eosinophils. Representative images of 2mm human airway incubated overnight with and without eosinophils. Immunoreactive
eotaxin (green) and MBP (red) are shown. (a) shows absence of primary antibodies, (b) image shows epithelium and airway wall eotaxin
(green), and (c) image shows epithelium and airway wall eotaxin (green) and MBP (red) (confocal microscopy 400x).
briefexposureperiods(15min)likelylimitsaccessofMBPto
airway surface cells, such as the airway epithelium. However,
our study provides the ﬁrst detailed description of the
distribution andlocalization of MBPandhuman eosinophils
in nonsensitized small human airways following in vitro
incubation. This permitted a detailed examination of the
time and concentration dependence of MBP’s distribution
through airway tissue.
In this study, we used surgically discarded human lung
specimens to obtain third- to sixth-generation bronchi.
Freshly isolated human eosinophils, as well as previously
isolated eosinophil-derived MBP, were used to study the
localization and distribution of both eosinophils and MBP
within bronchial segments following in vitro incubation.
Ourdataindicatethateosinophilsrapidly(<10min)adhered
to human airway tissue (Figure 2(a))a sw e l la st ob o t h
cultured human airway myocytes (Figure 2(b)) and primary
cultures of airway epithelium. These results are consistent
with the data by Hughes et al. [38] that freshly isolated
eosinophils from healthy donors rapidly attach to ASMC
in vitro, an eﬀect that involves VCAM-1 and ICAM-1
and is modulated by TNF-alpha. In addition, though IL-
5 may upregulate integrin-dependent eosinophil adhesion
to airway epithelium [39], a signiﬁcant eosinophil adhe-
sion to unstimulated airway epithelium is independent of
CD18/ICAM-1 [40]. We quantiﬁed eosinophil binding to
unstimulated cultured airway myocytes and airway epithe-
lium to be 10% and 20%, respectively. In our experiment
all human airways incubated 18h either with and without
eosinophils expressed immunoreactive Eotaxin which was
not diﬀerent in airway epithelium versus within the airway
media. It is likely that Eotaxin or other constitutively
expressed chemokines (Rantes) and adhesion molecules
(ICAM-1, VCAM-1) were likely responsible for eosinophil
migration within the airway wall [41, 42].
Following 18–24h incubation of bronchial segments
with eosinophils, eosinophils were found to adhere to the
epithelial layer as well as migrate within the airway wall
and localize to areas that included the smooth muscle layer
(Figures 3(a) and 3(b)). We determined that ∼22% of airway
wall eosinophils are juxtaposed with airway myocytes. These
ﬁndings are similar to clinical studies by Haley et al. [19],
Tulic et al. [20], Van [4], and Prins [5]; each of whom
noted that in small human airways taken from asthmatics
eosinophils were found predominately in the “outer” layer
between the smooth muscle and the adventia. Though
stimulated airway smooth muscle cells produce eotaxin [41,
43], a potent chemoattractant for eosinophils, little study
has been done to analyze the proximity of eosinophils and
airway myocytes in subjects with asthma or experimental
models of asthma. Moreover, in none of these human above
studies was an analysis of the extracellular deposition of
granule proteins, nor a precise localization of the eosinophils
in relative distance and distribution to myocytes and airway
neurons.
Following overnight incubation with eosinophils in
human airway, eosinophil degranulation was evident by two
patterns of extracellular MBP deposition: a broad linear
deposition along both the adventitial and epithelial surfaces,
and the discrete focal deposition within the airway media,
including the airway myocyte layer (Figure 4). This latter
pattern represented both MBP contained within eosinophils
as well as discrete focal deposition found surrounding
eosinophil degranulated “ghosts”. We calculated that the
immunologically detected volume of distribution of MBP
within the airway wall from single degranulated eosinophils
is ∼300μm3. This takes into account the diﬀusion of MBP
away from the degranulated eosinophil, as well as the
zone of clearing of MBP where the eosinophil resided (i.e.,
eosinophil “ghost”, Figure 5). Given the approximate content
of MBP within an eosinophil as 8.98 × 10
−9 mg (MW =
14,000) [44], the estimated concentration of MBP in these
discrete deposits within the airway is approximately 2.14 ×
10
−3 M. This concentration is signiﬁcantly greater than the
concentration of MBP (10μM/mL, or 7.14 × 10
−7 M) which
is known to be toxic to and causes erosion of the epithelium
[45]. Moreover, we have previously shown [18] that these
concentrations are well within the range to alter basal, as
well as agonist-elicited intracellular calcium mobilization
in cultured airway myocytes. The above ﬁndings are notMediators of Inﬂammation 11
surprising given MBP’s highly reactive sulfhydryl content
allowing MBP the ability to readily aggregate with itself and
other proteins [31].
Alternatively, when human airways were exposed to
exogenous MBP, the distribution of MBP within the air-
way wall occurred strictly in a time- and concentration-
dependent manner. At brief exposure times of MBP for
1min, only limited, MBP deposition to the epithelial and
adventitial surface of the airway occurred. As the exposure
time lengthened to 1 hour MBP penetration to cells within
the media of the airway wall occurred. Finally, following
overnight incubation, MBP could be detected easily within
the smooth muscle layer. This latter eﬀect was also con-
centration dependent (Figures 6 and 7). Our results diﬀer
from those of a recent in vivo study [46] which indicated
that in 22 patients with chronic rhinosinusitis (CRS) all
tissuespecimensshowedintacteosinophils, andextracellular
MBP deposition was found only within luminal mucus.
These results suggested that eosinophils might be found
beneath the sinus epithelium but only degranulate outside
of tissue within mucus. However, our data support the
hypothesis that eosinophil degranulation and release of MBP
may occur within the airway wall and may contribute to the
pathophysiology observed in asthma.
Others have suggested a role of eosinophil-derived
MBP as a cause of M2 muscarinic receptor dysfunction.
Speciﬁcally, in histologic airway sections from humans who
have died from acute asthma, eosinophils are found near
PGP 9.5 positive nerves [47]. Moreover, these investigators
determined that, in antigen-challenged guinea pigs, MBP
may allosterically bind to M2 muscarinics receptor thereby
inducing AHR in vivo [48, 49]. In a latter study they showed
that functional antagonism of MBP with the systemically
administered polyanion heparin reversed this AHR [17].
Additionally, Gu et al. [50, 51] have demonstrated that MBP
potentiates the excitability of neurons by inhibition of the
sustained delayed-rectiﬁer voltage-gated K+ current and the
fast-inactivating K+ current. As such, MBP release near
airway wall sensory neurons may elicit airway hyperrespon-
siveness via C-ﬁber aﬀerent activation. However, current
understanding suggests a minimal role of the vagal nervous
system in clinical asthma. However, in neither of the above
experimentsdidinvestigatorstakeintoaccountadirecteﬀect
of MBP at the level of the airway myocyte, a ﬁnding that we
previously noted [18]. Speciﬁcally, we have shown that MBP
augments airway myocyte intracellular calcium regulation.
Though our experiments were conducted in vitro in non-
sensitized tissue, we did not ﬁnd a speciﬁc recruitment
of eosinophils, nor extracellular MBP to airway neuronal
loci compared to other sites within the airway wall. Thus,
mechanistically sensitization may be necessarily related to
eosinophil migration and recruitment speciﬁcally to sites of
airway neurons.
The functional role of MBP in asthma models has
recently been challenged in a sensitized ovalbumin model
of asthma using mMBP-1 knockout mice [52]. Though
OVA-induced increases in AHR to nonspeciﬁc stimuli were
not mediated by mMBP-1, this model may not require
eosinophil degranulation for observed increases in AHR, the
temporal and spatial release of MBP may not elicit an AHR
response,orothereosinophil-derivedgranuleproteinmaybe
responsible for AHR. However, in other models of asthma,
AHR has been shown to correlate with extracellular MBP
deposition [30] including localization of eosinophils to the
airway smooth muscle band [53]. In fact, neutralization of
endogenous eosinophil released MBP by speciﬁc antiserum
prevents bronchial hyperreactivity in antigen-challenged
guinea pigs [54].
In conclusion, in nonsensitized small human airway,
eosinophils adhere, migrate within the airway wall, and
undergo spontaneous degranulation of MBP. We acknowl-
edge that while the presence of COPD-related inﬂammatory
signaling within some of our tissue specimens may have
inﬂuenced the migration of eosinophils it was unlikely to
inﬂuence the extracellular pattern of deposition of MBP, nor
the interpretation of MBPs rather restricted diﬀusion and
ability to deposit within the airway wall, and hence inﬂuence
directly myocyte function in vivo.
Immunohistochemically, MBP’s volume of distribution
is restricted to ∼300μm3 from the degranulated eosinophil
producing locally high concentrations within the smooth
muscle layer nearing 10
−3 M. Because of the restricted
nature of MBP’s diﬀusion its distribution is both time and
concentration dependent, and also depends on its form
of delivery, that is, within intact eosinophils or as native
MBP. Brief in vitro applications of MBP, especially only
to the luminal surface of the airway, may not capture
the complete physiologic inﬂuence of MBP on eliciting
AHR. In this in vitro model of eosinophil incubation with
bronchial segments, there does not appear to be speciﬁc
recruitment of eosinophils to airway neurons. Thus, our
ﬁndings suggest that studies and therapeutical interventions
designed speciﬁcally to the target eosinophil and MBP need
to consider the spatial and concentration eﬀects of granule
proteins released within the airway wall as well as the airway
lumen.
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